SG11201910099WA - Methods for treatment of alport syndrome - Google Patents
Methods for treatment of alport syndromeInfo
- Publication number
- SG11201910099WA SG11201910099WA SG11201910099WA SG11201910099WA SG 11201910099W A SG11201910099W A SG 11201910099WA SG 11201910099W A SG11201910099W A SG 11201910099WA SG 11201910099W A SG11201910099W A SG 11201910099WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- alport syndrome
- mir
- modified oligonucleotide
- oligonucleotide targeted
- Prior art date
Links
- 208000024985 Alport syndrome Diseases 0.000 title abstract 6
- 208000003215 hereditary nephritis Diseases 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 4
- 108091062762 miR-21 stem-loop Proteins 0.000 abstract 4
- 108091041631 miR-21-1 stem-loop Proteins 0.000 abstract 4
- 108091044442 miR-21-2 stem-loop Proteins 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000001934 delay Effects 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000722270 Regulus Species 0.000 abstract 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000028208 end stage renal disease Diseases 0.000 abstract 1
- 201000000523 end stage renal failure Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 229910052709 silver Inorganic materials 0.000 abstract 1
- 239000004332 silver Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501699P | 2017-05-04 | 2017-05-04 | |
| PCT/US2018/031094 WO2018204788A1 (en) | 2017-05-04 | 2018-05-04 | Methods for treatment of alport syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910099WA true SG11201910099WA (en) | 2019-11-28 |
Family
ID=62223298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910099W SG11201910099WA (en) | 2017-05-04 | 2018-05-04 | Methods for treatment of alport syndrome |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210100828A1 (enExample) |
| EP (1) | EP3618838A1 (enExample) |
| JP (2) | JP2020518633A (enExample) |
| KR (1) | KR20190141770A (enExample) |
| CN (2) | CN116585344A (enExample) |
| AU (1) | AU2018261792A1 (enExample) |
| BR (1) | BR112019022824A2 (enExample) |
| CA (1) | CA3062316A1 (enExample) |
| CL (1) | CL2019003153A1 (enExample) |
| MA (1) | MA50749A (enExample) |
| MX (1) | MX2019013158A (enExample) |
| SG (1) | SG11201910099WA (enExample) |
| WO (1) | WO2018204788A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022076452A1 (en) * | 2020-10-05 | 2022-04-14 | Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital | Combination therapy for alport renal disease |
| CN120731923B (zh) * | 2025-09-05 | 2025-11-04 | 内蒙古医科大学附属医院(内蒙古自治区心血管研究所) | 一种Alport综合征小鼠NMD逃逸模型的构建方法及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080152700A1 (en) * | 2004-06-01 | 2008-06-26 | Reza Sheikhnejad | Methods and compositions for the inhibition of gene expression |
| KR101877698B1 (ko) * | 2008-08-25 | 2018-07-12 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| EP2825648B1 (en) * | 2012-03-15 | 2018-09-05 | CuRNA, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
| BR112014026639A8 (pt) * | 2012-04-25 | 2018-01-16 | Regulus Therapeutics Inc | compostos , métodos de inibição da atividade de mir-21 , método para diminuir a expressão de colágeno , método para tratar , prevenir ou atrasar o início de uma doença , método de tratamento de um distúrbio fibroproliferativo e usos de um composto. |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| GB201507926D0 (en) * | 2015-05-08 | 2015-06-24 | Proqr Therapeutics N V | Improved treatments using oligonucleotides |
-
2018
- 2018-05-04 SG SG11201910099W patent/SG11201910099WA/en unknown
- 2018-05-04 MA MA050749A patent/MA50749A/fr unknown
- 2018-05-04 AU AU2018261792A patent/AU2018261792A1/en not_active Abandoned
- 2018-05-04 WO PCT/US2018/031094 patent/WO2018204788A1/en not_active Ceased
- 2018-05-04 MX MX2019013158A patent/MX2019013158A/es unknown
- 2018-05-04 EP EP18726668.9A patent/EP3618838A1/en not_active Withdrawn
- 2018-05-04 KR KR1020197035568A patent/KR20190141770A/ko not_active Ceased
- 2018-05-04 CA CA3062316A patent/CA3062316A1/en active Pending
- 2018-05-04 US US16/607,971 patent/US20210100828A1/en not_active Abandoned
- 2018-05-04 CN CN202310591916.8A patent/CN116585344A/zh active Pending
- 2018-05-04 CN CN201880037914.1A patent/CN110740737A/zh active Pending
- 2018-05-04 BR BR112019022824A patent/BR112019022824A2/pt not_active IP Right Cessation
- 2018-05-04 JP JP2019560355A patent/JP2020518633A/ja active Pending
-
2019
- 2019-11-04 CL CL2019003153A patent/CL2019003153A1/es unknown
-
2021
- 2021-09-14 US US17/474,264 patent/US20220133769A1/en not_active Abandoned
-
2023
- 2023-02-17 JP JP2023023048A patent/JP2023075111A/ja active Pending
- 2023-08-09 US US18/446,743 patent/US20240115598A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20240115598A1 (en) | 2024-04-11 |
| CN110740737A (zh) | 2020-01-31 |
| WO2018204788A1 (en) | 2018-11-08 |
| EP3618838A1 (en) | 2020-03-11 |
| CN116585344A (zh) | 2023-08-15 |
| JP2020518633A (ja) | 2020-06-25 |
| RU2019139261A3 (enExample) | 2021-09-06 |
| KR20190141770A (ko) | 2019-12-24 |
| CL2019003153A1 (es) | 2020-03-27 |
| CA3062316A1 (en) | 2018-11-08 |
| AU2018261792A1 (en) | 2020-01-02 |
| RU2019139261A (ru) | 2021-06-04 |
| BR112019022824A2 (pt) | 2020-06-09 |
| US20210100828A1 (en) | 2021-04-08 |
| MX2019013158A (es) | 2020-02-07 |
| MA50749A (fr) | 2020-03-11 |
| JP2023075111A (ja) | 2023-05-30 |
| US20220133769A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201909777YA (en) | Modulatory polynucleotides | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11201806342SA (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
| SG11201807573VA (en) | Methods for providing single-stranded rna | |
| SG11201407859YA (en) | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists | |
| SG11201805120YA (en) | Zika virus vaccine | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201909856XA (en) | Mesenchymal lineage precursor or stem cells with enhanced immunosuppression | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201901220XA (en) | Methods of processing a fluid including a recombinant therapeutic protein and use thereof | |
| SG11202000136YA (en) | Preparation comprising vonoprazan | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201909520VA (en) | Rna for treatment of autoimmune diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof |